ArticleJAMA network open2021
Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma.
Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma.BMC gastroenterology · 2025Pooled it
- Pooled it
- Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy.Frontiers in immunology · 2022Trial
- Radiomics-based outcome prediction for irinotecan-TACE in colorectal liver metastases: advanced analysis from the prospective CIREL trial.European radiology · 2026Article
- Advances in stimuli-responsive hydrogels for liver disease therapy: mechanisms, applications, and translational perspectives.Drug delivery and translational research · 2026Review
- Review
- Smartly Assembled near-Micron RF-Responsive Agents Bridge Transarterial Embolization and Immunothermal Potentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Transcatheter arterial chemoembolization plus ablation therapy versus liver resection for hepatocellular carcinoma with clinically significant portal hypertension by an inverse probability of treatment weighting analysis.Updates in surgery · 2026Article
- Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablation.Hepatology international · 2026Article
- Efficacy of Sequential Transarterial Chemoembolization after Stereotactic Body Radiation Therapy versus Radiation Therapy Alone for Recurrent Hepatocellular Carcinoma: A Propensity Score-matched Analysis.Journal of clinical and translational hepatology · 2026Article
- Clinical efficacy of MWA via the caudal‒cranial direction puncture pathway for small hepatocellular carcinoma at the hepatic dome: 3 years of follow-up.BMC surgery · 2026Article
- Efficacy Analysis of Capsule Integrity and TACE Combined with Microwave Ablation versus Microwave Ablation Alone for Primary Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Trans-Arterial Chemoembolization Combined with Microwave Ablation versus Microwave Ablation Alone for 3-5 cm Hepatocellular Carcinoma: A Multicenter Retrospective Study.Journal of hepatocellular carcinoma · 2026Article
- Superselective Lipiodol CT-guided Microwave Ablation for Small Hepatocellular Carcinoma: A Novel Imaging Guidance Strategy.Current medical imaging · 2026Article
- Hepatocellular Carcinoma in the Eastern World: Screening, Diagnosis, Staging and Treatment.Current pharmaceutical design · 2026Review
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver cancer · 2025Article
- Sustained AFP-L3 or DCP expression is associated with progression risk and inferior outcomes in unresectable hepatocellular carcinoma.Clinical and experimental medicine · 2025Article
- Review
- Review
- Machine Learning-Based Model for Predicting Recurrence-Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients.Cancer medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The long-term outcomes of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) are not determined. Objective: To report the long-term outcomes of TACE-RFA. Design, Setting, and Participants: This cohort study analyzed long-term follow-up data from a phase 3 randomized clinical trial of adults with early HCC conducted from October 2006 to June 2009. Participants were randomly assigned to the TACE-RFA group or the RFA group in a 1:1 ratio and followed up approximately 6 years after the trial was closed. Data analysis was performed March 2020. Exposure: In the TACE-RFA group, TACE was performed first, and RFA was done 2 weeks later. Main Outcomes and Measures: Overall survival (OS) and recurrence-free survival (RFS). Results: Of 189 patients who were included (mean [SD] age, 54.3 [12.0] years; 146 [77.2%] men), 94 and 95 patients were assigned to the TACE-RFA group and RFA group, respectively, with their baseline characteristics well matched. Three patients in each group were lost to follow-up. The 5-year and 7-year OS rates for the TACE-RFA group vs the RFA group were 52.0% and 36.4% vs 43.2% and 19.4%, respectively (hazard ratio [HR], 0.55; 95% CI, 0.39-0.78; P = .001). The 5-year and 7-year RFS rates for the TACE-RFA group vs the RFA group were 41.4% and 34.5% vs 27.4% and 18.1%, respectively (HR, 0.66; 95% CI, 0.49-0.89; P = .007). On subgroup analysis comparing patients who had tumors larger than 3 cm with those who had tumors 3 cm or smaller, the OS and RFS survival rates in the TACE-RFA group (HR, 3.20; 95% CI, 1.91-5.35, P < .001) were significantly better than those in the RFA group (HR, 2.03; 95% CI, 1.30-3.17; P = .002). Conclusions and Relevance: In this cohort study, combined RFA and TACE was associated with better survival than RFA alone on long-term follow-up. Patients with tumors 3 cm or smaller did not benefit as well as patients with tumors larger than 3 cm from the combined treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.